Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price reached a new 52-week low during trading on Thursday . The company traded as low as C$0.02 and last traded at C$0.02, with a volume of 10000 shares traded. The stock had previously closed at C$0.02.
Quest PharmaTech Price Performance
The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52. The stock has a 50 day moving average price of C$0.02 and a two-hundred day moving average price of C$0.03. The firm has a market capitalization of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of -0.07.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Featured Articles
- Five stocks we like better than Quest PharmaTech
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
- Permian Resources Rally Faces a Test
- Google Cloud Just Gave Rezolve AI a Major Vote of Confidence
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
